Jubilant Biosys Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jubilant Biosys Ltd.
‘The Next Tulip Mania?’ – Fidelity, Gurnet, Biogen Put A Lens To Funding, Valuations
Venture capital funding for biotechs remains aplenty even as listed companies’ stock prices drop. Biogen’s Papadopoulos, Fidelity’s Kaul and Gurnet’s and ex-Sanofi Viehbacher deliberate on whether there is a valuation disconnect and if this is the next "tulip mania."
Fortress Biotech: A Drug Financing Experiment Expands
Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.
Start-Up Quarterly Statistics, Q2 2016
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.
Sanofi Taps Jubilant Expertise For Metabolic Disorder Drug Discovery
India's biggest contract research firm Jubilant Life Sciences says it has joined forces with the German arm of France's biggest pharma firm Sanofi to discover new therapies for treating metabolic disorders.
- Contract Research, Toxicology Testing-CRO
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.